Literature DB >> 15195089

Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa.

David T Woodley1, Douglas R Keene, Tom Atha, Yi Huang, Kathi Lipman, Wei Li, Mei Chen.   

Abstract

Dystrophic epidermolysis bullosa (DEB) is a family of inherited mechano-bullous disorders that are caused by mutations in the type VII collagen gene and for which ex vivo gene therapy has been considered. To develop a simpler approach for treating DEB, we evaluated the feasibility of protein-based therapy by intradermally injecting human recombinant type VII collagen into mouse skin and a DEB human skin equivalent transplanted onto mice. The injected collagen localized to the basement membrane zone of both types of tissues, was organized into human anchoring fibril structures and reversed the features of DEB disease in the DEB skin equivalent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195089     DOI: 10.1038/nm1063

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  43 in total

1.  Induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Stavros Spiliopoulos; Nikolaos Davanos
Journal:  Ann Transl Med       Date:  2015-12

2.  Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.

Authors:  Jon Cogan; Jacqueline Weinstein; Xinyi Wang; Yingping Hou; Sabrina Martin; Andrew P South; David T Woodley; Mei Chen
Journal:  Mol Ther       Date:  2014-07-23       Impact factor: 11.454

3.  Bone marrow cells can manipulate healing.

Authors:  Vincent Falanga
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

4.  Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-/- keratinocytes in vitro.

Authors:  Olga Igoucheva; Aislinn Kelly; Jouni Uitto; Vitali Alexeev
Journal:  J Invest Dermatol       Date:  2007-12-13       Impact factor: 8.551

Review 5.  [Orogenital and conjunctival involvement in hereditary and autoimmune blistering diseases].

Authors:  M Laimer; C M Lanschützer; M Emberger; E Nischler; J Stoiber; H Hintner
Journal:  Hautarzt       Date:  2009-11       Impact factor: 0.751

6.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

Review 7.  Recessive Dystrophic Epidermolysis Bullosa: Advances in the Laboratory Leading to New Therapies.

Authors:  David T Woodley; Mei Chen
Journal:  J Invest Dermatol       Date:  2015-07       Impact factor: 8.551

Review 8.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

9.  Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells.

Authors:  Jakub Tolar; Akemi Ishida-Yamamoto; Megan Riddle; Ron T McElmurry; Mark Osborn; Lily Xia; Troy Lund; Catherine Slattery; Jouni Uitto; Angela M Christiano; John E Wagner; Bruce R Blazar
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

10.  A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.

Authors:  Anja Fritsch; Stefan Loeckermann; Johannes S Kern; Attila Braun; Michael R Bösl; Thorsten A Bley; Hauke Schumann; Dominik von Elverfeldt; Dominik Paul; Miriam Erlacher; Dirk Berens von Rautenfeld; Ingrid Hausser; Reinhard Fässler; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.